Hematuria is a medical condition indicated by the presence of blood in the urine; under normal circumstances, urine does not contain RBCs. This can result in serious issue that may also cause kidney stones, urinary tract infection, and other inherited diseases. The hematuria treatment market, based on treatment, is segmented into drugs, therapies, and others. As hematuria is associated with various indications such as the UTI, kidney stone, blood cancer, bladder stones, and prostate cancer, the drugs used for these indications can also be used for its treatment. Alfuzosin, ciprofloxacin, doxazosin, ibuprofen, and tamsulosin are among the commonly used drugs for the hematuria treatment. This is a preferred treatment type as the drugs can be administered at home and in healthcare settings.
This report contains market size and forecasts of Hematuria Treatment in Global, including the following market information:
Global Hematuria Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Hematuria Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Macroscopic Hematuria Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Hematuria Treatment include AstraZeneca, Bristol-Myers Squibb Company, F. HOFFMANN-LA ROCHE LTD., GlaxoSmithKline plc., Janssen Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc. and Sun Pharmaceutical Industries Ltd and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Hematuria Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hematuria Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Hematuria Treatment Market Segment Percentages, by Type, 2021 (%)
Macroscopic Hematuria
Microscopic Hematuria
Idiopathic Hematuria
Jogger’s Hematuria
Global Hematuria Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Hematuria Treatment Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics
Others
Global Hematuria Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Hematuria Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hematuria Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Hematuria Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
AstraZeneca
Bristol-Myers Squibb Company
F. HOFFMANN-LA ROCHE LTD.
GlaxoSmithKline plc.
Janssen Pharmaceuticals
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Sun Pharmaceutical Industries Ltd
Boehringer Ingelheim International GmbH